FDA approves expanded Camzyos label for obstructive HCM patients weighing 30 kg or more
BMY•The FDA approved an expanded label for Bristol Myers Squibb’s Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy in patients weighing 30 kg or more, including pediatric patients. Phase 3 SCOUT-HCM data showed a 48 mmHg greater reduction in Valsalva LVOT gradient versus placebo at week 28.
